LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article ; Online: Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation

    Daniel Fife / M Soledad Cepeda / Alan Baseman / Henry Richards / Peter Hu / H Lynn Starr / Anthony G Sena

    PLoS ONE, Vol 13, Iss 2, p e

    A retrospective database study.

    2018  Volume 0193453

    Abstract: Observational studies of switching from branded to generic formulations of the same drug substance often lack appropriate comparators for the subjects who switched. Three generic formulations were deemed equivalent to Concerta: an authorized generic (AG) ...

    Abstract Observational studies of switching from branded to generic formulations of the same drug substance often lack appropriate comparators for the subjects who switched. Three generic formulations were deemed equivalent to Concerta: an authorized generic (AG) identical except for external packaging, and two other generics (EG).Compare the incidence of a combined endpoint (switching back to Concerta, changing the use of immediate release methylphenidate (MPH), stopping all long-acting methylphenidate, or starting a new medication) among people switched from Concerta to the AG versus the EG.Cohort study from the Truven CCAE database of people aged 6 to 65 diagnosed with ADHD, treated with Concerta, and switched to the EG or to the AG formulation.In the EG arm 24.6% and in the AG arm 19.7% of subjects switched back to Concerta. The proportion of subjects meeting the combined endpoint was 39.5% in the EG arm, 32.9% in the AG arm, a crude risk ratio of 1.20 (95% CI 0.94, 1.54). After adjustment by propensity score stratification, the adjusted odds ratio (OR) was 1.23 (95% CI 0.90, 1.70). In an unplanned analysis using a different method of adjustment, the adjusted OR was 1.00 (95% CI 0.69, 1.44).This study did not detect a difference between the proportion of people who met the study endpoint in the two study arms, i.e. between those who switched to a generic formulation that was identical to Concerta except for external packaging and those who switched to the comparison generics. The high incidence of the combined endpoint in the AG arm demonstrates the need for an appropriate comparator in studies of this type.ClinicalTrials.gov NCT02730572.
    Keywords Medicine ; R ; Science ; Q
    Language English
    Publishing date 2018-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Book ; Online: Using Real World Data to Understand HIV and COVID-19 in the U.S.A. and Spain

    Julianna Kohler / Kristin M Kostka / Rupa Makadia / Roger Paredes / Talita Duarte-Salles / Scott L Duvall / Michael Matheny / Kristine E Lynch / Alison Cheng / Asieh Golozar / Jennifer C E Lane / Anthony G Sena / Peter J Rijnbeek / Daniel R Morales / Patrick B Ryan / Christian G Reich / George Siberry / Daniel Prieto-Alhambra

    Characterizing Co-Infected Patients Across the Care Cascade

    2020  

    Abstract: Objective: Most patients severely affected by COVID-19 have been elderly and patients with underlying chronic disease such as diabetes, cardiovascular disease, or respiratory disease. People living with HIV (PLHIV) may have greater risk of contracting or ...

    Abstract Objective: Most patients severely affected by COVID-19 have been elderly and patients with underlying chronic disease such as diabetes, cardiovascular disease, or respiratory disease. People living with HIV (PLHIV) may have greater risk of contracting or developing severe COVID-19 due to the underlying HIV infection or higher prevalence of comorbidities. Design: This is a cohort study, including PLHIV diagnosed, hospitalized, or requiring intensive services for COVID-19. Methods: Data sources include routine electronic medical record or claims data from the U.S. and Spain. Patient demographics, comorbidities, and medication history are described. Results: Four data sources had a population of HIV/COVID-19 coinfected patients ranging from 288 to 4606 lives. PLHIV diagnosed with COVID-19 were younger than HIV-negative patients diagnosed with COVID-19. PLHIV diagnosed with COVID-19 diagnosis had similar comorbidities as HIV-negative COVID-19 patients with higher prevalence of those comorbidities and history of severe disease. Treatment regimens were similar between PLHIV diagnosed with COVID-19 or PLHIV requiring intensive services. Conclusions: Our study uses routine practice data to explore HIV impact on COVID-19, providing insight into patient history prior to COVID-19. We found that HIV and COVID-19 coinfected patients have higher prevalence of underlying comorbidities such as cardiovascular and respiratory disease as compared to HIV-negative COVID-19 infected patients. We also found that, across the care cascade, co-infected patients who received intensive services were more likely to have more serious underlying disease or a history of more serious events as compared to PLHIV who were diagnosed with COVID-19.
    Keywords COVID-19 ; HIV ; Prevalence ; Comorbidities ; covid19
    Subject code 610 ; 310
    Publishing date 2020-11-13
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases

    Erica A. Voss / Azza Shoaibi / Lana Yin Hui Lai / Clair Blacketer / Thamir Alshammari / Rupa Makadia / Kevin Haynes / Anthony G. Sena / Gowtham Rao / Sebastiaan van Sandijk / Clement Fraboulet / Laurent Boyer / Tanguy Le Carrour / Scott Horban / Daniel R. Morales / Jordi Martínez Roldán / Juan Manuel Ramírez-Anguita / Miguel A. Mayer / Marcel de Wilde /
    Luis H. John / Talita Duarte-Salles / Elena Roel / Andrea Pistillo / Raivo Kolde / Filip Maljković / Spiros Denaxas / Vaclav Papez / Michael G. Kahn / Karthik Natarajan / Christian Reich / Alex Secora / Evan P. Minty / Nigam H. Shah / Jose D. Posada / Maria Teresa Garcia Morales / Diego Bosca / Honorio Cadenas Juanino / Antonio Diaz Holgado / Miguel Pedrera Jiménez / Pablo Serrano Balazote / Noelia García Barrio / Selçuk Şen / Ali Yağız Üresin / Baris Erdogan / Luc Belmans / Geert Byttebier / Manu L.N.G. Malbrain / Daniel J. Dedman / Zara Cuccu / Rohit Vashisht / Atul J. Butte / Ayan Patel / Lisa Dahm / Cora Han / Fan Bu / Faaizah Arshad / Anna Ostropolets / Fredrik Nyberg / George Hripcsak / Marc A. Suchard / Dani Prieto-Alhambra / Peter R. Rijnbeek / Martijn J. Schuemie / Patrick B. Ryan

    EClinicalMedicine, Vol 58, Iss , Pp 101932- (2023)

    a multinational retrospective cohort studyResearch in context

    2023  

    Abstract: Summary: Background: Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim was to characterise the incidence rates of ... ...

    Abstract Summary: Background: Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim was to characterise the incidence rates of AESIs following SARS-CoV-2 infection in patients and compare these to historical rates in the general population. Methods: A multi-national cohort study with data from primary care, electronic health records, and insurance claims mapped to a common data model. This study's evidence was collected between Jan 1, 2017 and the conclusion of each database (which ranged from Jul 2020 to May 2022). The 16 pre-specified prevalent AESIs were: acute myocardial infarction, anaphylaxis, appendicitis, Bell's palsy, deep vein thrombosis, disseminated intravascular coagulation, encephalomyelitis, Guillain- Barré syndrome, haemorrhagic stroke, non-haemorrhagic stroke, immune thrombocytopenia, myocarditis/pericarditis, narcolepsy, pulmonary embolism, transverse myelitis, and thrombosis with thrombocytopenia. Age-sex standardised incidence rate ratios (SIR) were estimated to compare post-COVID-19 to pre-pandemic rates in each of the databases. Findings: Substantial heterogeneity by age was seen for AESI rates, with some clearly increasing with age but others following the opposite trend. Similarly, differences were also observed across databases for same health outcome and age-sex strata. All studied AESIs appeared consistently more common in the post-COVID-19 compared to the historical cohorts, with related meta-analytic SIRs ranging from 1.32 (1.05 to 1.66) for narcolepsy to 11.70 (10.10 to 13.70) for pulmonary embolism. Interpretation: Our findings suggest all AESIs are more common after COVID-19 than in the general population. Thromboembolic events were particularly common, and over 10-fold more so. More research is needed to contextualise post-COVID-19 complications in the longer term. Funding: None.
    Keywords COVID-19 ; Observational research ; OMOP CDM ; Adverse events of special interest ; Medicine (General) ; R5-920
    Language English
    Publishing date 2023-04-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Book ; Online: Heterogeneity and temporal variation in the management of COVID-19

    Albert Prats-Uribe / Anthony G. Sena / Lana Yin Hui Lai / Waheed-Ul-Rahman Ahmed / Heba Alghoul / Osaid Alser / Thamir M Alshammari / Carlos Areia / William Carter / Paula Casajust / Dalia Dawoud / Asieh Golozar / Jitendra Jonnagaddala / Paras Mehta / Gong Menchung / Daniel R Morales / Fredrik Nyberg / Jose D Posada / Martina Recalde /
    Elena Roel / Karishma Shah / Nigam Shah / Lisa M Schilling / Vignesh Subbian / David Vizcaya / Andrew Williams / Lin Zhang / Ying Zhang / Hong Zhu / Li Liu / Peter Rijnbeek / George Hripcsak / Jennifer C.E Lane / Edward Burn / Christian Reich / Marc A Suchard / Talita Duarte-Salles / Kristin Kostka / Patrick B Ryan / Daniel Prieto-Alhambra

    a multinational drug utilization study including 71,921 hospitalized patients from China, South Korea, Spain, and the United States of America

    2020  

    Abstract: Objectives: A plethora of medicines have been repurposed or used as adjunctive therapies for COVID-19. We characterized the utilization of medicines as prescribed in routine practice amongst patients hospitalized for COVID-19 in South Korea, China, Spain, ...

    Abstract Objectives: A plethora of medicines have been repurposed or used as adjunctive therapies for COVID-19. We characterized the utilization of medicines as prescribed in routine practice amongst patients hospitalized for COVID-19 in South Korea, China, Spain, and the USA. Design: International network cohort Setting: Hospital electronic health records from Columbia University Irving Medical Centre (NYC, USA), Stanford (CA, USA), Tufts (MA, USA), Premier (USA), Optum EHR (USA), department of veterans affairs (USA), NFHCRD (Honghu, China) and HM Hospitals (Spain); and nationwide claims from HIRA (South Korea) Participants: patients hospitalized for COVID-19 from January to June 2020 Main outcome measures: Prescription/dispensation of any medicine on or 30 days after hospital admission date Analyses: Number and percentage of users overall and over time Results: 71,921 people were included: 304 from China, 2,089 from Spain, 7,599 from South Korea, and 61,929 from the USA. A total of 3,455 medicines were identified. Common repurposed medicines included hydroxychloroquine (<2% in NFHCRD to 85.4% in HM), azithromycin (4.9% in NFHCRD to 56.5% in HM), lopinavir/ritonavir (<3% in all US but 34.9% in HIRA and 56.5% in HM), and umifenovir (0% in all except 78.3% in NFHCRD). Adjunctive medicines were used with great variability, with the ten most used treatments being (in descending order): bemiparin, enoxaparin, heparin, ceftriaxone, aspirin, vitamin D, famotidine, vitamin C, dexamethasone, and metformin. Hydroxychloroquine and azithromycin increased rapidly in use in March-April but declined steeply in May-June. Conclusions: Multiple medicines were used in the first months of COVID-19 pandemic, with substantial geographic and temporal variation. Hydroxychloroquine, azithromycin, lopinavir-ritonavir, and umifenovir (in China only) were the most prescribed repurposed medicines. Antithrombotics, antibiotics, H2 receptor antagonists and corticosteroids were often used as adjunctive treatments. Research is needed on the comparative risk and benefit of these treatments in the management of COVID-19.
    Keywords COVID-19 ; Electronic health records ; Hydroxychloroquine ; Lopinavir/Ritonavir ; Umifenovir ; Azithromycin ; covid19
    Subject code 950
    Publishing date 2020-09-25
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Book ; Online: Renin-angiotensin system blockers and susceptibility to COVID-19

    Daniel R Morales / Mitchell M Conover / Seng Chan You / Nicole Pratt / Kristin Kostka / Talita Duarte Salles / Sergio Fernandez Bertolin / Maria Aragon / Scott L. DuVall / Kristine Lynch / Thomas Falconer / Kees van Bochove / Cynthia Sung / Michael E. Matheny / Christophe G. Lambert / Fredrik Nyberg / Thamir M AlShammari / Andrew E. Williams / Rae Woong Park /
    James Weaver / Anthony G. Sena / Martijn J. Schuemie / Peter R. Rijnbeek / Ross D. Williams / Jennifer C.E Lane / Albert Prats Uribe / Lin Zhang / Carlos Areia / Harlan Krumholz / Daniel Prieto Alhambra / Patrick B Ryan / George Hripcsak / Marc A Suchard

    a multinational open science cohort study

    2020  

    Abstract: Introduction: Angiotensin converting enzyme inhibitors (ACEs) and angiotensin receptor blockers (ARBs) could influence infection risk of coronavirus disease (COVID-19). Observational studies to date lack pre-specification, transparency, rigorous ... ...

    Abstract Introduction: Angiotensin converting enzyme inhibitors (ACEs) and angiotensin receptor blockers (ARBs) could influence infection risk of coronavirus disease (COVID-19). Observational studies to date lack pre-specification, transparency, rigorous ascertainment adjustment and international generalizability, with contradictory results. Methods: Using electronic health records from Spain (SIDIAP) and the United States (Columbia University Irving Medical Center and Department of Veterans Affairs), we conducted a systematic cohort study with prevalent ACE, ARB, calcium channel blocker (CCB) and thiazide diuretic (THZ) use to determine relative risk of COVID-19 diagnosis and related hospitalization outcomes. The study addressed confounding through large-scale propensity score adjustment and negative control experiments. Results: Following over 1.1 million antihypertensive users identified between November 2019 and January 2020, we observed no significant difference in relative COVID-19 diagnosis risk comparing ACE/ARB vs CCB/THZ monotherapy (hazard ratio: 0.98; 95% CI 0.84 - 1.14), nor any difference for mono/combination use (1.01; 0.90 - 1.15). ACE alone and ARB alone similarly showed no relative risk difference when compared to CCB/THZ monotherapy or mono/combination use. Directly comparing ACE vs. ARB demonstrated a moderately lower risk with ACE, non-significant for monotherapy (0.85; 0.69 - 1.05) and marginally significant for mono/combination users (0.88; 0.79 - 0.99). We observed, however, no significant difference between drug- classes for COVID-19 hospitalization or pneumonia risk across all comparisons. Conclusion: There is no clinically significant increased risk of COVID-19 diagnosis or hospitalization with ACE or ARB use. Users should not discontinue or change their treatment to avoid COVID-19.
    Keywords COVID-19 ; Electronic health records ; Angiotensin converting enzyme inhibitor ; Angiotensin receptor blocker ; Calcium channel blocker ; Thiazide diuretic ; Risk ; covid19
    Subject code 610
    Publishing date 2020-06-12
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Book ; Online: Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis

    Jennifer C.E Lane / James Weaver / Kristin Kostka / Talita Duarte-Salles / Maria Tereza F Abrahao / Heba Alghoul / Osaid Alser / Thamir M Alshammari / Carlos Areia / Juan M. Banda / Patricia Biedermann / Edward Burn / Paula Casajust / Kristina Fišter / Jill Hardin / Laura Hester / George Hripcsak / Benjamin Skov Kaas-Hansen / Sajan Khosla /
    Spyros Kolovos / Kristine E. Lynch / Rupa Makadia / Paras P. Mehta / Daniel R Morales / Henry Morgan-Stewart / Mees Mosseveld / Danielle Newby / Fredrik Nyberg / Anna Ostropolets / Rae Woong Park / Albert Prats-Uribe / Gowtham A. Rao / Christian Reich / Peter Rijnbeek / Anthony G. Sena / Azza Shoaibi / Matthew Spotnitz / Vignesh Subbian / Marc A Suchard / David Vizcaya / Haini Wen / Marcel de Wilde / Junqing Xie / Seng Chan You / Lin Zhang / Simon Lovestone / Patrick B Ryan / Daniel Prieto-Alhambra

    a multi-national network cohort study

    2020  

    Abstract: Objectives Concern has been raised in the rheumatological community regarding recent regulatory warnings that hydroxychloroquine used in the COVID-19 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident ... ...

    Abstract Objectives Concern has been raised in the rheumatological community regarding recent regulatory warnings that hydroxychloroquine used in the COVID-19 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation, or psychosis associated with hydroxychloroquine as used for rheumatoid arthritis (RA). Methods New user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and US). RA patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine (active comparator) and followed up in the short (30-day) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation, and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HR), with estimates pooled where I2<40%. Results 918,144 and 290,383 users of hydroxychloroquine and sulfasalazine, respectively, were included. No consistent risk of psychiatric events was observed with short-term hydroxychloroquine (compared to sulfasalazine) use, with meta-analytic HRs of 0.96 [0.79-1.16] for depression, 0.94 [0.49-1.77] for suicide/suicidal ideation, and 1.03 [0.66-1.60] for psychosis. No consistent long-term risk was seen, with meta-analytic HRs 0.94 [0.71-1.26] for depression, 0.77 [0.56-1.07] for suicide/suicidal ideation, and 0.99 [0.72-1.35] for psychosis. Conclusions Hydroxychloroquine as used to treat RA does not appear to increase the risk of depression, suicide/suicidal ideation, or psychosis compared to sulfasalazine. No effects were seen in the short or long term. Use at higher dose or for different indications needs further investigation.
    Keywords COVID-19 ; Hydroxychloroquine ; Safety ; Rheumatoid Arthritis ; Psychosis ; Depression ; Sulfasalazine ; Risk ; covid19
    Subject code 310
    Publishing date 2020-08-07
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Book ; Online: Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States

    Talita Duarte-Salles / David Vizcaya / Andrea Pistillo / Paula Casajust / Anthony G. Sena / Lana Yin Hui Lai / Albert Prats-Uribe / Waheed-Ul-Rahman Ahmed / Thamir M Alshammari / Heba Alghoul / Osaid Alser / Edward Burn / Seng Chan You / Carlos Areia / Clair Blacketer / Scott DuVall / Thomas Falconer / Sergio Fernandez-Bertolin / Stephen Fortin /
    Asieh Golozar / Mengchun Gong / Eng Hooi Tan / Vojtech Huser / Pablo Iveli / Daniel R. Morales / Fredrik Nyberg / Jose D. Posada / Martina Recalde / Elena Roel / Lisa M. Schilling / Nigam H. Shah / Karishma Shah / Marc A. Suchard / Lin Zhang / Ying Zhang / Andrew E. Williams / Christian G. Reich / George Hripcsak / Peter Rijnbeek / Patrick Ryan / Kristin Kostka / Daniel Prieto-Alhambra

    an international network cohort study

    2020  

    Abstract: Objectives To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19. Secondly, to describe health outcomes amongst children/adolescents ... ...

    Abstract Objectives To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19. Secondly, to describe health outcomes amongst children/adolescents diagnosed with previous seasonal influenza. Design International network cohort. Setting Real-world data from European primary care records (France/Germany/Spain), South Korean claims and US claims and hospital databases. Participants Diagnosed and/or hospitalized children/adolescents with COVID-19 at age <18 between January and June 2020; diagnosed with influenza in 2017-2018. Main outcome measures Baseline demographics and comorbidities, symptoms, 30-day in-hospital treatments and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome (ARDS), multi-system inflammatory syndrome (MIS-C), and death. Results A total of 55,270 children/adolescents diagnosed and 3,693 hospitalized with COVID-19 and 1,952,693 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were all more common among those hospitalized vs diagnosed with COVID-19. The most common COVID-19 symptom was fever. Dyspnea, bronchiolitis, anosmia and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital treatments for COVID-19 included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids (6.8% to 37.6%), famotidine (9.0% to 28.1%), and antithrombotics such as aspirin (2.0% to 21.4%), heparin (2.2% to 18.1%), and enoxaparin (2.8% to 14.8%). Hospitalization was observed in 0.3% to 1.3% of the COVID-19 diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. Thirty-day outcomes including pneumonia, ARDS, and MIS-C were more frequent in COVID-19 than influenza. Conclusions Despite negligible fatality, complications including pneumonia, ARDS and MIS-C were more frequent in children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal symptoms could help differential diagnosis. A wide range of medications were used for the inpatient management of pediatric COVID-19.
    Keywords COVID-19 ; Demographics ; Comorbidities ; Symptoms ; Treatments ; Health outcomes ; Children ; Influenza ; Real-world data ; Primary care records ; Claims ; Hospital databases ; covid19
    Subject code 360
    Publishing date 2020-10-30
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Book ; Online: Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom

    Martina Recalde / Elena Roel / Andrea Pistillo / Anthony G Sena / Albert Prats-Uribe / Waheed Ul-Rahman Ahmed / Heba Alghoul / Thamir M Alshammari / Osaid Alser / Carlos Areia / Edward Burn / Paula Casajust / Dalia Dawoud / Scott L DuVall / Thomas Falconer / Sergio Fernandez-Bertolin / Asieh Golozar / Mengchun Gong / Lana Yin Hui Lai /
    Jennifer C.E Lane / Kristine E Lynch / Michael E Matheny / Paras P Mehta / Daniel R Morales / Karthik Natarjan / Fredrik Nyberg / Jose D Posada / Christian G Reich / Lisa M Schilling / Karishma Shah / Nigham H Shah / Vignesh Subbian / Lin Zhang / Hong Zhu / Patrick Ryan / Daniel Prieto-Alhambra / Kristin Kostka / Talita Duarte-Salles

    2020  

    Abstract: Background: COVID-19 may differentially impact people with obesity. We aimed to describe and compare the demographics, comorbidities, and outcomes of obese patients with COVID-19 to those of non-obese patients with COVID-19, or obese patients with ... ...

    Abstract Background: COVID-19 may differentially impact people with obesity. We aimed to describe and compare the demographics, comorbidities, and outcomes of obese patients with COVID-19 to those of non-obese patients with COVID-19, or obese patients with seasonal influenza. Methods: We conducted a cohort study based on outpatient/inpatient care, and claims data from January to June 2020 from the US, Spain, and the UK. We used six databases standardized to the OMOP common data model. We defined two cohorts of patients diagnosed and/or hospitalized with COVID-19. We created corresponding cohorts for patients with influenza in 2017-2018. We followed patients from index date to 30 days or death. We report the frequency of socio-demographics, prior comorbidities, and 30-days outcomes (hospitalization, events, and death) by obesity status. Findings: We included 627 044 COVID-19 (US: 502 650, Spain: 122 058, UK: 2336) and 4 549 568 influenza (US: 4 431 801, Spain: 115 224, UK: 2543) patients. The prevalence of obesity was higher among hospitalized COVID-19 (range: 38% to 54%) than diagnosed COVID-19 (30% to 47%), or diagnosed/hospitalized influenza (15% to 48%) patients. Obese hospitalized COVID-19 patients were more often female and younger than non-obese COVID-19 patients or obese influenza patients. Obese COVID-19 patients were more likely to have prior comorbidities, present with cardiovascular and respiratory events during hospitalization, require intensive services, or die compared to non-obese COVID-19 patients. Obese COVID-19 patients were also more likely to require intensive services or die compared to obese influenza patients, despite presenting with fewer comorbidities. Interpretation: We show that obesity is more common among COVID-19 than influenza patients, and that obese patients present with more severe forms of COVID-19 with higher hospitalization, intensive services, and fatality than non-obese patients. These data are instrumental for guiding preventive strategies of COVID-19 infection and complications
    Keywords COVID-19 ; Obesity ; Hospital admission ; Case-fatality rate ; covid19
    Subject code 610
    Publishing date 2020-09-03
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study

    Edward Burn / Seng Chan You / Anthony G. Sena / Kristin Kostka / Hamed Abedtash / Maria Tereza F. Abrahão / Amanda Alberga / Heba Alghoul / Osaid Alser / Thamir M. Alshammari / Maria Aragon / Carlos Areia / Juan M. Banda / Jaehyeong Cho / Aedin C. Culhane / Alexander Davydov / Frank J. DeFalco / Talita Duarte-Salles / Scott DuVall /
    Thomas Falconer / Sergio Fernandez-Bertolin / Weihua Gao / Asieh Golozar / Jill Hardin / George Hripcsak / Vojtech Huser / Hokyun Jeon / Yonghua Jing / Chi Young Jung / Benjamin Skov Kaas-Hansen / Denys Kaduk / Seamus Kent / Yeesuk Kim / Spyros Kolovos / Jennifer C. E. Lane / Hyejin Lee / Kristine E. Lynch / Rupa Makadia / Michael E. Matheny / Paras P. Mehta / Daniel R. Morales / Karthik Natarajan / Fredrik Nyberg / Anna Ostropolets / Rae Woong Park / Jimyung Park / Jose D. Posada / Albert Prats-Uribe / Gowtham Rao / Christian Reich

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 11

    Abstract: Detailed knowledge of the characteristics of COVID-19 patients helps with public health planning. Here, the authors use routinely-collected data from seven databases in three countries to describe the characteristics of >30,000 patients admitted with ... ...

    Abstract Detailed knowledge of the characteristics of COVID-19 patients helps with public health planning. Here, the authors use routinely-collected data from seven databases in three countries to describe the characteristics of >30,000 patients admitted with COVID-19 and compare them with those admitted for influenza in previous years.
    Keywords Science ; Q
    Language English
    Publishing date 2020-10-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis

    Jennifer C E Lane / James Weaver / Kristin Kostka / Talita Duarte-Salles / Maria Tereza F Abrahao / Heba Alghoul / Osaid Alser / Thamir M Alshammari / Patricia Biedermann / Juan M Banda / Edward Burn / Paula Casajust / Mitchell M Conover / Aedin C Culhane / Alexander Davydov / Scott L DuVall / Dmitry Dymshyts / Sergio Fernandez-Bertolin / Kristina Fišter /
    Jill Hardin / Laura Hester / George Hripcsak / Benjamin Skov Kaas-Hansen / Seamus Kent / Sajan Khosla / Spyros Kolovos / Christophe G Lambert / Johan van der Lei / Kristine E Lynch / Rupa Makadia / Andrea V Margulis / Michael E Matheny / Paras Mehta / Daniel R Morales / Henry Morgan-Stewart / Mees Mosseveld / Danielle Newby / Fredrik Nyberg / Anna Ostropolets / Rae Woong Park / Albert Prats-Uribe / Gowtham A Rao / Christian Reich / Jenna Reps / Peter Rijnbeek / Selva Muthu Kumaran Sathappan / Martijn Schuemie / Sarah Seager / Anthony G Sena / Azza Shoaibi / Matthew Spotnitz / Marc A Suchard / Carmen O Torre / David Vizcaya / Haini Wen / Marcel de Wilde / Junqing Xie / Seng Chan You / Lin Zhang / Oleg Zhuk / Patrick Ryan / Daniel Prieto-Alhambra / OHDSI-COVID-19 consortium

    The Lancet Rheumatology

    a multinational, retrospective study

    2020  

    Abstract: Background Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We ... ...

    Abstract Background Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to determine the risk associated with its use in routine care in patients with rheumatoid arthritis. Methods In this multinational, retrospective study, new user cohort studies in patients with rheumatoid arthritis aged 18 years or older and initiating hydroxychloroquine were compared with those initiating sulfasalazine and followed up over 30 days, with 16 severe adverse events studied. Self-controlled case series were done to further establish safety in wider populations, and included all users of hydroxychloroquine regardless of rheumatoid arthritis status or indication. Separately, severe adverse events associated with hydroxychloroquine plus azithromycin (compared with hydroxychloroquine plus amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, the Netherlands, Spain, the UK, and the USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (HRs) according to drug use. Estimates were pooled where the I² value was less than 0·4. Findings The study included 956 374 users of hydroxychloroquine, 310 350 users of sulfasalazine, 323 122 users of hydroxychloroquine plus azithromycin, and 351 956 users of hydroxychloroquine plus amoxicillin. No excess risk of severe adverse events was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. Selfcontrolled case series confirmed these findings. However, long-term use of hydroxychloroquine appeared to be associated with increased cardiovascular mortality (calibrated HR 1·65 [95% CI 1·12–2·44]). Addition of azithromycin appeared to be associated with an increased risk of 30-day cardiovascular mortality (calibrated HR 2·19 [95% CI 1·22–3·95]), chest pain or angina (1·15 [1·05–1·26]), and heart failure (1·22 [1·02–1·45]). Interpretation Hydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality. The addition of azithromycin increases the risk of heart failure and cardiovascular mortality even in the short term. We call for careful consideration of the benefit–risk trade-off when counselling those on hydroxychloroquine treatment.
    Keywords Hydroxychloroquine ; Sulfasalazine ; Azithromycin ; Adverse events ; Rheumatoid arthritis ; Safety ; COVID-19 ; Pneumonia ; covid19
    Subject code 610
    Publishing date 2020-10-13
    Publishing country eu
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top